Suppr超能文献

胆管癌:分子异常与细胞起源。

Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin.

机构信息

Department of Oncology, Istituto Supeirore di Sanità, Rome, Italy.

出版信息

Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221128689. doi: 10.1177/15330338221128689.

Abstract

Cholangiocarcinomas (CCAs) are a group of heterogeneous epithelial malignancies that can originate at the level of any location of the biliary tree. These tumors are relatively rare but associated with a high rate of mortality. CCAs are morphologically and molecularly heterogeneous and for their location can be distinguished as intracellular and extracellular, subdivided into perihilar and distal. Recent epidemiological, molecular, and cellular studies have supported that the consistent heterogeneity observed for CCAs may result from the convergence of various key elements mainly represented by risk factors, heterogeneity of the associated molecular abnormalities at genetic and epigenetic levels and by different potential cells of origin. These studies have consistently contributed to better defining the pathogenesis of CCAs and to identify in some instances new therapeutic targets. Although the therapeutic progress were still limited, these observations suggest that a better understanding of the molecular mechanisms underlying CCA in the future will help to develop more efficacious treatment strategies.

摘要

胆管癌(CCA)是一组异质性上皮恶性肿瘤,可起源于胆道的任何部位。这些肿瘤相对罕见,但死亡率很高。CCA 在形态和分子上存在异质性,根据其位置可分为细胞内型和细胞外型,进一步分为肝门周围型和远端型。最近的流行病学、分子和细胞研究支持这样一种观点,即 CCA 观察到的一致异质性可能是由各种关键因素汇聚的结果,这些因素主要包括危险因素、遗传和表观遗传水平上相关分子异常的异质性以及不同的潜在起源细胞。这些研究有助于更好地定义 CCA 的发病机制,并在某些情况下确定新的治疗靶点。尽管治疗进展仍然有限,但这些观察结果表明,未来对 CCA 分子机制的更好理解将有助于开发更有效的治疗策略。

相似文献

1
Cholangiocarcinoma: Molecular Abnormalities and Cells of Origin.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221128689. doi: 10.1177/15330338221128689.
2
Latest advances in the pathological understanding of cholangiocarcinomas.
Expert Rev Gastroenterol Hepatol. 2016;10(1):113-27. doi: 10.1586/17474124.2016.1104246. Epub 2015 Oct 22.
3
Decreasing Albumin mRNA Expression in Cholangiocarcinomas along the Bile Duct Tree.
Pathobiology. 2024;91(5):338-344. doi: 10.1159/000538706. Epub 2024 May 19.
4
Pathology of Cholangiocarcinomas.
Curr Oncol. 2022 Dec 26;30(1):370-380. doi: 10.3390/curroncol30010030.
5
Cholangiocellular Carcinoma.
Digestion. 2017;95(3):181-185. doi: 10.1159/000454763. Epub 2017 Mar 14.
6
Pathological survey of precursor lesions in cholangiocarcinoma.
J Hepatobiliary Pancreat Sci. 2023 Jul;30(7):893-903. doi: 10.1002/jhbp.1308. Epub 2023 Feb 18.
7
Cholangiocarcinoma.
Pathologica. 2021 Jun;113(3):158-169. doi: 10.32074/1591-951X-252.
8
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Cancer Treat Res Commun. 2021;27:100354. doi: 10.1016/j.ctarc.2021.100354. Epub 2021 Mar 16.
9
[Cholangiocarcinoma-diagnosis, classification, and molecular alterations].
Pathologe. 2020 Sep;41(5):488-494. doi: 10.1007/s00292-020-00808-6.
10
Pathologic classification of cholangiocarcinoma: New concepts.
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):277-93. doi: 10.1016/j.bpg.2015.02.006. Epub 2015 Feb 17.

引用本文的文献

2
Role, mechanism, and application of N6-methyladenosine in hepatobiliary carcinoma.
World J Gastrointest Oncol. 2025 Jun 15;17(6):105140. doi: 10.4251/wjgo.v17.i6.105140.
3
The Immune Landscape and Its Potential for Immunotherapy in Advanced Biliary Tract Cancer.
Curr Oncol. 2024 Dec 31;32(1):24. doi: 10.3390/curroncol32010024.
4

本文引用的文献

1
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
3
4
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18.
6
Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1- Mediated Gemcitabine Chemoresistance.
Front Oncol. 2022 Apr 8;12:860339. doi: 10.3389/fonc.2022.860339. eCollection 2022.
7
Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma.
Front Med (Lausanne). 2022 Mar 31;9:857140. doi: 10.3389/fmed.2022.857140. eCollection 2022.
8
TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma.
Front Genet. 2022 Mar 25;13:844800. doi: 10.3389/fgene.2022.844800. eCollection 2022.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验